Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Renal Cell 64Carcinoma, Hepatocellular 26Prostatic Neoplasms 22Neoplasm Metastasis 19Neoplasms 18Carcinoma, Non-Small-Cell Lung 16Kidney Neoplasms 14Osteosarcoma 9Neuroendocrine Tumors 9Colorectal Neoplasms 9Carcinoma, Transitional Cell 9Sarcoma 8Carcinoma, Medullary 8Urinary Bladder Neoplasms 7Sarcoma, Ewing 7Melanoma 7Breast Neoplasms 7Brain Neoplasms 7Thyroid Neoplasms 6Ovarian Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Recurrence 5Pancreatic Neoplasms 5Lung Neoplasms 5Carcinoma 5Urethral Neoplasms 4Triple Negative Breast Neoplasms 4Multiple Myeloma 4Thyroid Cancer, Papillary 3Small Cell Lung Carcinoma 3

Interventions

Cetuximab 2Alpelisib 2toripalimab 1sintilimab 1rocakinogene sifuplasmid 1raltitrexed 1cabozantinib 1VGX-3100 1Radiotherapy, Intensity-Modulated 1Metformin 1MEDI0457 1Fluorouracil 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Head and Neck Squamous Cell Cancer × cabozantinib × Clear all
NCT03667482 2024-07-23

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
20 enrolled
Head & Neck

Head and Neck Squamous Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡